Clinical Trial Detail

NCT ID NCT03289910
Title Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

atypical chronic myeloid leukemia

myelofibrosis

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

chronic myelomonocytic leukemia

essential thrombocythemia

myeloproliferative neoplasm

Therapies

Carboplatin + Topotecan + Veliparib

Carboplatin + Topotecan

Age Groups: adult senior

No variant requirements are available.